NASDAQ$CSTL
Castle Biosciences Inc · Q2 2021 earnings
Q2 2021 earnings · · Investor relations
Briefing
Reported revenues of $22.8 million and increased total dermatology test report volume by 70%.
Castle Biosciences reported strong Q2 2021 results with a 79% increase in revenue compared to Q2 2020. The company also saw a 70% increase in DecisionDx-Melanoma test reports and raised its 2021 revenue guidance to $89-93 million.
- Revenues were $22.8 million, a 79% increase compared to $12.7 million during the same period in 2020.
- Total gene expression profile test reports delivered in the second quarter of 2021 were 7,007, compared to 3,314 in the same period of 2020.
- DecisionDx-Melanoma test reports delivered in the second quarter of 2021 were 5,128, compared to 3,008 in the second quarter of 2020, an increase of 70%.
- The company is raising 2021 revenue guidance to $89-93 million from $80-83 million.
Headline financials
Revenue & EPS history
Castle Biosciences · Revenue · Quarterly
$22.8M
Forward guidance
Castle Biosciences is increasing its previously issued guidance for anticipated total revenue in 2021. The Company now anticipates generating $89-93 million in total revenue in 2021, compared to the previously provided guidance of $80-83 million.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2021
+0.1%
Avg return
Earnings day
-2.1%
Avg return
5 days after
+0.7%
Avg return
30 days after
41%
13 / 32 earnings
Positive
+21.8%
Q3 2025
Best reaction
-28.0%
Q4 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +0.6% | -22.6% | -14.4% | |
| Q4 2025 | -7.3% | -11.6% | -26.2% | |
| Q3 2025 | +21.8% | +27.1% | +52.4% | |
| Q1 2025 | -11.7% | -10.5% | -9.2% | |
| Q4 2024 | -14.2% | -15.7% | -21.1% | |
| Q3 2024 | -6.0% | +0.4% | -3.8% | |
| Q2 2024 | +11.8% | +20.4% | +29.8% | |
| Q1 2024 | +10.5% | +8.1% | +5.6% | |
| Q4 2023 | -28.0% | -15.4% | -11.7% | |
| Q3 2023 | +14.5% | +14.6% | +27.2% | |
| Q2 2023 | +12.3% | +7.0% | +17.6% | |
| Q1 2023 | -0.2% | +2.6% | +3.0% | |
| Q4 2022 | -7.7% | -0.3% | -10.2% | |
| Q3 2022 | -6.0% | -23.7% | -0.4% | |
| Q2 2022 | +0.3% | +11.1% | -12.6% | |
| Q1 2022 | -4.1% | -6.8% | +3.1% | |
| Q4 2021 | +4.5% | -5.4% | -1.5% | |
| Q3 2021 | -7.2% | -13.2% | -23.2% | |
| Q2 2021 | -4.9% | -10.3% | +6.5% | |
| Q1 2021 | -9.5% | -8.5% | +17.5% | |
| Q4 2020 | -9.9% | -6.9% | +2.3% | |
| Q3 2020 | -3.3% | -2.6% | +12.3% | |
| Q2 2020 | +0.1% | -1.1% | +19.8% | |
| Q1 2020 | +17.1% | +18.9% | +22.4% | |
| Q1 2019 | +17.1% | +18.9% | +22.4% | |
| Q1 2018 | -1.5% | -18.2% | -4.7% | |
| Q4 2019 | -1.5% | -18.2% | -4.7% | |
| Q3 2018 | +20.0% | -7.0% | -6.1% | |
| Q3 2019 | +18.2% | +30.3% | +32.9% | |
| Q2 2018 | -6.9% | -9.0% | -33.8% | |
| Q2 2019 | -6.9% | -9.0% | -33.8% | |
| Q4 2018 | -6.9% | -9.0% | -33.8% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro